Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2022; 28(47): 6788-6790
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6788
The potential role of the three-dimensional-bioprinting model in screening and developing drugs
Chao-Lin Deng, Bin Wu
Chao-Lin Deng, Bin Wu, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Author contributions: Wu B designed and revised the manuscript; Deng CL wrote the manuscript.
Supported by CAMS Innovation Fund for Medical Sciences, No. 2021-1-I2M-015, and National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-B-003.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Wu, MD, PhD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, China. wubin0279@hotmail.com
Received: October 15, 2022
Peer-review started: October 15, 2022
First decision: October 26, 2022
Revised: October 28, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 21, 2022
Processing time: 65 Days and 6.5 Hours
Core Tip

Core Tip: Chemotherapy is the main treatment option for inoperable colorectal cancer (CRC). We recently read an article about the anti-cancer effects of Diiminoquinone. We feel obliged to express our opinion on this article on drug screening models and the difference between pathologic subtypes in CRC and hope it could deepen understanding for the reader.